Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Current Deferred Tax Assets (2018 - 2021)

Historic Current Deferred Tax Assets for China SXT Pharmaceuticals (SXTC) over the last 3 years, with Q3 2021 value amounting to $504522.0.

  • China SXT Pharmaceuticals' Current Deferred Tax Assets fell 487.39% to $504522.0 in Q3 2021 from the same period last year, while for Sep 2021 it was $504522.0, marking a year-over-year decrease of 487.39%. This contributed to the annual value of $547807.0 for FY2021, which is 728.33% up from last year.
  • As of Q3 2021, China SXT Pharmaceuticals' Current Deferred Tax Assets stood at $504522.0, which was down 487.39% from $547807.0 recorded in Q1 2021.
  • In the past 5 years, China SXT Pharmaceuticals' Current Deferred Tax Assets registered a high of $547807.0 during Q1 2021, and its lowest value of $46508.0 during Q3 2018.
  • Over the past 3 years, China SXT Pharmaceuticals' median Current Deferred Tax Assets value was $510617.0 (recorded in 2020), while the average stood at $427965.2.
  • The largest annual percentage gain for China SXT Pharmaceuticals' Current Deferred Tax Assets in the last 5 years was 728.33% (2021), contrasted with its biggest fall of 487.39% (2021).
  • Quarter analysis of 3 years shows China SXT Pharmaceuticals' Current Deferred Tax Assets stood at $46508.0 in 2018, then skyrocketed by 1040.39% to $530372.0 in 2020, then decreased by 4.87% to $504522.0 in 2021.
  • Its last three reported values are $504522.0 in Q3 2021, $547807.0 for Q1 2021, and $530372.0 during Q3 2020.